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SARS-CoV-2, first emerged in the Hubei province of China in December 2019. The efficient 
transmission of the virus from person-to-person has contributed to the global spread of infection, 
better known as the COVID-19 pandemic. Patients with the highly infectious disease display flu-
like symptoms such as cold and fever. The COVID-19 pandemic, caused by SARS-CoV-2, has 
become a public health emergency with over 200 countries affected. Genome sequence analysis 
has discovered that the virus is similar to that of SARS-CoV and MERS-CoV. Despite this, 
however, attempts to control SARS-CoV-2 with antiviral agents used to treat prior SARS-CoV 
and MERS-CoV infections have been found to be ineffective. As the rate of infection and deaths 
from COVID-19 increases, the pressure to find a vaccine solution builds. Efforts to develop 
antiviral agents against SARS-CoV-2 continue and the potential of multi-epitope vaccines will 
be further explored in this review. Multiple epitope targets of the spike (S) protein of SARS-
CoV-2 are analyzed for their immunogenicity, stability, safety, and potential as vaccine 
candidates. The vaccine constructs discussed give promise of becoming vaccine candidates but 
require further in vitro and in vivo experimentation. 
 
Background 
Coronaviruses are classified under the Orthocoronaviridae subfamily (order: Nidovirales, 
subordination: Cornidovirineae, family: Coronaviridae)1 and are grouped into four genera: α-/β-
/γ-/δ-CoV. Due to α- and β-CoV infecting mammals, the β-CoV is of particular interest during 
the 2020 coronavirus pandemic. A novel β-CoV, now known as SARS-CoV-2, was identified 
from pneumonia cases in Wuhan, China in December 2019. The virus was named SARS-CoV-2 
by the International Committee for Taxonomy of Viruses but is more commonly known by the 
name COVID-19 provided by the WHO.2 SARS-Cov-2 is a more pathogenic form compared to 
that of the SARS-CoV of 2002 and the MERS-CoV of 2013. SARS-CoV and MERS-CoV are 
both coronaviruses that also infected human populations through zoonotic transmission and 
spread by close human contact. The SARS-CoV-2 genome shares around 82% sequence identity 
with SARS- and MERS-CoV and over 92% sequence identify regarding essential enzymes and 
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structural proteins.3 Such a high level of matching has uncovered common pathogenicity 
amongst the three coronaviruses.   
 
Coronaviruses are a type of enveloped virus containing a positive single-stranded RNA genome. 
In SARS coronaviruses, four glycoproteins are present including the spike (S), membrane (M), 
envelope (E) and nucleocapsid (N) proteins. These glycoproteins assist in virus particle 
assembly, replication and release. The S protein is highly important due to its role in binding to 
the host cell-surface receptor and allowing the virus to enter the host cell (Figure 1). The S 
protein consists of the S1 and S2 subunits where the S1 unit contains the receptor binding 
domain (RBD) required for attaching to host cell receptors and the S2 unit has other domains 
needed for fusion and intracellular trafficking inside the cell.4 Specifically, the S protein 
promotes cell entry by binding to angiotensin-converting enzyme 2 (ACE2) as well as to host 
proteases, like transmembrane serine protease 2 (TMPRSS2), that prime the S protein.8 
TMPRSS2 activates the S protein and cleaves the ACE2 receptor to initiate binding of the virus 
to the host cell. Virion particles enter the host cell by endocytosis and its genome attaches to the 
host’s ribosomes. When this occurs, translation of 2 co-terminal and large polyproteins are 
processed further by proteolysis mediated by proteases 3CLpro and PLpro. These mediators slice 
large polyproteins into smaller components for folding and packaging new virions, contributing 
to the spread of the viral infection in the host.3  
 
  
Fig. 1 Schematic representation of the SARS-CoV-2 structure and its mode of host entry.3 
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While the viral infection spreads through the host, the host cell entry of SARS-CoV-2 occurs 
mainly in the upper respiratory tract of the alveolar epithelial type II cells where its pathogenic 
effects are also observed. Studies have further clarified that the ACE2 and TMPRSS2 receptors 
are particularly expressed in alveolar epithelial type II cells.16 As the viral infection continues to 
spread, the host immune system recognizes the virus and/or its epitopes and stimulates an innate 
or adaptive immune response. Pathogen recognition receptors (PRRs) present on the immune 
cells, toll-like receptors (TLR) 3, 7 and 8, identify the virus and initiate the production of 
interferon (IFN). The infection and replication of SARS-CoV-2 dampens the response of the 
produced IFN by dodging innate immune cells. As this occurs, the presence of monocytes, 
neutrophils, and adaptive immune cells initiates increased pro-inflammatory cytokine 
production. Within the helper T cells, Th1 and Th17 cells with viral epitopes may usher cytokine 
storms that result in pulmonary edema or pneumonia. Cytotoxic T cells are recruited to the site 
of infection to kill any infected cells in the lungs. B cells, like T cells, recognize viral proteins 
and activate antibody production in response.9  
 
How does SARS-CoV-2 spread among humans and what are the clinical symptoms?  
SARS-CoV-2 is a novel virus associated with acute respiratory disease. The infection, COVID-
19, spreads via droplets, respiratory secretions, contact surfaces, and direct human contact 
through the respiratory tract.3,5 The virus has a suggested incubation period of 1-14 days 
although the majority of cases are around 3-7 days. Patients with COVID-19 have symptoms 
including fever, malaise, cough, and flu-like symptoms.6,15 Severe problems are commonly seen 
in elderly patients as well as those with comorbidities. Those in critical condition have displayed 
acute respiratory distress syndrome (ARDS), respiratory failure, multiple organ failure, and 
death.7   
 
Possible multi-epitope vaccine use against SARS-CoV-2 
SARS-CoV-2, like SARS-CoV and MERS-CoV, causes severe respiratory illness and possible 
death for comorbid patients. The potential adaptive mutations in the SARS-CoV-2 genome allow 
the virus to be highly pathogenic, making it difficult to develop drug therapeutics and vaccines.3 
Despite the difficulty, multiple pharmaceutical research companies are currently developing 
vaccine candidates to tackle the prevention of COVID-19 infections. There are hopes in vaccine 
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development as phylogenetic analysis of different SARS-CoV-2 strains’ glycoproteins indicate 
close relation to one another, meaning that a vaccine targeting one strain would be effective 
against all other strains (Figure 2).  
 
 
Fig. 2 Phylogenetic analysis of spike glycoprotein in HCoV-NL63, HCoV-229E, HCoV-OC43, HKU-1, 
MERS-CoV, SARS-CoV and SARS-CoV-2.8 
 
One approach to the outbreak of SARS-CoV-2 is the development of multi-epitope vaccine 
constructs. These vaccines are made up of a series of or overlapping peptides that are an ideal 
solution to the prevention and treatment of viral infections and tumors.18 Multi-epitope subunit 
vaccines are a novel strategy in the prevention and treatment of infectious diseases and are 
developed via immunoinformatics methods and computational analyses. This innovative 
approach allows researchers to identify immunogenic and highly conserved epitopes from 
bacterial and viral antigens. CD4+ and CD8+ epitopes can be used both separately and in 
combination to develop a broad range of vaccine candidates. The construct of the vaccines 
provide the ability to combat a variety of pathogens as well as elicit cellular and humoral 
responses in human hosts. Administration of these vaccines allows the mock epitopes to be 
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presented to the major histocompatibility complex (MHC) where their corresponding T-cell 
receptors proliferate and generate appropriate immune responses.16  
 
Benefits and drawbacks of a multi-epitope vaccine design 
Despite being a new approach to vaccine development, multi-epitope vaccines promise potential 
by being cost-effective, highly safe, decreasing time to design, water soluble, using natural 
adjuvants, stable under simple storage conditions, and providing satisfactory preclinical 
evaluations.13,22 In addition, they do not require microbial culturing and surpass many wet lab 
experiments.16 They are a safer option to pursue due to the absence of an entire pathogen, 
making the vaccine highly specific and stable. Whole pathogen immunizations include this 
drawback, with concerns of causing autoimmune or strong allergic reactions.22 Regarding the 
design concepts, a multi-epitope vaccine construct contains unique aspects compared to classical 
vaccines containing a whole pathogen or single-epitope vaccines. In particular, they consist of 
cytotoxic T-cells, T helper cells, and B cell epitopes, all of which can induce robust cellular and 
humeral immune responses concurrently. With the addition of an adjuvant, the vaccine may have 
increased immunogenicity and long-lasting immune responses. Also, the inclusion of multiple 
epitopes from different virus antigens widens the range of targeted viruses. Finally, pathological 
immune responses or adverse effects may be reduced through the administration of a multi-
epitope vaccine as components triggering this cascades are unutilized.18 With such features, the 
use of multi-epitope vaccines as a therapeutic agent against viral infections, especially SARS-
CoV-2, may be a future exploit. 
 
Although promising in vaccine development, several drawbacks of a multi-epitope vaccine 
approach include the selection of appropriate candidate antigenic epitopes as well as the 
development of an effective delivery system, usually by use of an adjuvant to enhance the 
immune response. Additionally, peptides are poor immunogens and require the use of adjuvants 
or a delivery system to aid in their ability to induce an immune response. They are prone to 
enzymatic degradation and are often not recognized equally by the whole outbred population.22 
In the race to develop a vaccine for SARS-CoV-2, peptide-based vaccines have been 
outperformed by mRNA vaccine candidates. These mRNA vaccines may also be a novel 
approach in vaccinology but their performance has proven potent immunity that is able to induce 
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Following epitope selection, adjuvants are commonly used in vaccines to strengthen the 
stimulation of an immune response while also protecting the antigen from degradation and 
transporting the respective antigen to the desired tissue. Adjuvants may replace the natural 
danger signal triggered by infection as the lack of a whole pathogen in the vaccine construct 
hinders strong native danger signals.22 Of the proposed epitope targets explored below, the use of 
beta-defensins as an adjuvant was a well favored method. Prior research has shown that vaccines 
containing defensin adjuvants activate the primary innate antiviral immune response and mediate 
other immunomodulatory activities against some viruses, including coronaviruses.19 Cholera 
Toxin B was also explored as an adjuvant with earlier studies citing its ability to increase 
systemic and mucosal immune responses with protein conjugates.21  
 
Review of proposed epitope targets in SARS-CoV-2 
Multi-epitopic subunit vaccines have become of interest due to their role in the viral structural 
proteins evoking a strong immune response. Studies have indicated that humoral and cell-
mediated immune responses play a role in protection from the S and N proteins of 
coronaviruses.12 With multi-epitopic subunit vaccines emerging as a new strategy in vaccine 
development, studies on vaccine constructs for SARS-CoV-2 have emerged. These vaccine 
constructs are designed using immunoinformatics methods and computational analysis where 
epitope predictions are performed by servers and then further selected based on their 
antigenicity, toxicity, allergenicity, and cross-reactivity with human proteomes.19 the predicted 
epitopes are attached by proper linkers. The vaccine construct is then physiochemically, 
immunologically, and structurally evaluated by bioinformatics tools to confirm validity and 
potency of the construct. The following provides a review of potential epitope targets in vaccine 
candidates.  
 
In a study performed at the India Institute of Technology Mandi, three structural proteins (S, N 
and E) capable of inducing a humoral and cell-mediated immune response were selected for a 
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multi-epitopic vaccine candidate. IEDB, NetCTL, and IFNepitope servers were used to predict B 
lymphocyte, helper T cell, cytotoxic T cell, and IFN-γ epitopes. A multi-epitopic vaccine was 
constructed using 48 selected high-scoring CTLs, 4 high-affinity HTLs, and 4 B-cell epitopes. 
These epitopes were linked together using the CTL linker (AAY), HTL linker (GPGPG), and B 
epitope linker (KK). To improve the immunogenicity of the vaccine, β-defensin-TLR-3 agonist 
was added as an adjuvant through an EAAAK linker at the N-terminal of the vaccine construct. 
The vaccine candidate and human toll-like receptor-3 (TLR-3) binding stability was observed by 
docking and molecular dynamic simulations. Residues at the N-terminal and middle region of the 
vaccine construct were shown to form stable interactions with the TLR-3. The vaccine construct 
was validated on the Ramachandran plot indicating that 88% of residues of the vaccine model 
lied within the favored and allowed regions. A comparison with the RAMPAGE serve had 
similar results with about 90.7% residues in the favored and allowed regions. The vaccine was 
found to be antigenic with a score of 0.566 through VaxiJen v2.0 and 0.845 through 
ANTIGENPro. With the vaccine candidate being antigenic, non-allergen, nontoxic, highly 
stable, immunogenic in nature and capable of INF- γ production,  researchers encourage 
continued experimentation to validate the multi-subunit vaccine by in vitro and in vivo studies.14  
 
Another study with collaboration between the University of Lahore, National University of 
Sciences and Technology and the Khawaja Muhammad Safdar Medical College, developed three 
multi-epitopic peptide vaccine candidates through the use of the immunoinformatics approach by 
predicting B-cell and T-cell epitopes (Fig 3)16. The S1 and S2 domains of spike proteins were 
analyzed while two of the three vaccine constructs were prioritized with T-cell and B-cell 
epitopes. The prioritized epitopes were then modeled using linkers and adjuvants. Further 
observation was done via 3D models demonstrating their physiochemical properties and 
potential interactions with ACE2, TLR2, TLR4, and HLA Superfamily alleles. In vaccine 1, four 
epitopes from the S1 domain were used. Three of the four epitopes were in the N-terminal 
domain of the S1 protein and the fourth was in the receptor binding domain (319-541). The 
particular locations of these four epitopes made a great potential target for antiviral therapeutics 
and vaccines due to the roles of the S1 subunit and RBD in viral entry of the host cell. Vaccine 2 
contrasted that of vaccine 1 by containing both weak and strong epitopes. 
506QPYRVVVLSFELLHA520 epitope was implemented due to its presence in the RBD while two 
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weak epitopes,731MTKTSVDCTMYICGD745 and 733KTSVDCTMY741, from the S2 domain were 
added to observe for binding affinity. Docking with TLR2, TLR4, and ACE2 indicated that the 
two S2 weak epitopes bound effectivity. In the binding from 31MTKTSVDCTMYICGD745, 
Thr192, Val197, Lys186, Thr187, and Ser186 bound to TLR4, Lys186 had an affinity for the ACE2 
receptor. 33KTSVDCTMY741 was found to overlap the other S2 epitope 
31MTKTSVDCTMYICGD745. The third vaccine construct was a modified version of vaccine 2 
including an additional B-cell epitope 369YNSASFSTFKCYGVSPTKLNDLCFT393 and the 
adjuvant beta defensin. In previous studies, β-defensin had been found to be a potent adjuvant 
when conjugated with MERS-CoV antigens.20 Adding this epitope and adjuvant ensured both a 
cellular and humoral immune response as observed by previous studies. Vaccine 3 was found to 
have considerable interactions with TLRs and HLA superfamily alleles as well as interactions 
between Cys93 and Phe94 from the B cell epitope and between Arg8 and Glu96 from the BCR. All 
proposed vaccines took into account the role of the spike proteins and the likelihood of the 
vaccines being presented by MHC-I and MHC-II. The vaccine constructs were validated ERRAT 
analysis and Ramachandran plots. The ERRAT scores for vaccines 1-3 were as follows: 74.1379, 
67.5676, and 74.2574, respectively. The Ramachandran plot analyses found that 97.1% residues 
were in the favored region for vaccine 1, 98.1% residues in the favored region for vaccine 2 and 
86.5% for vaccine 3. Of the three vaccine constructs, the Ramachandran plot values indicated 
vaccine 1 and 2 to be higher quality in their structure. Binding affinity validated by a 
HADDOCK web server noted that vaccine 1 had the highest interactive ability compared to 
vaccine 2 and 3. In addition, the antigenic potential of the three vaccines was tested via VaxiJen 
v2.0. All three vaccines were found to be antigenic with scores of 0.883591, 0.946425, and 
0.8853570, respectively. From these results, the suggested vaccine candidates display potential 
as antiviral agents. Researchers encourage further study of these potential epitope candidates by 
in vitro and in vivo experiments as they may block the viral interaction of ACE2 and spike 
glycoproteins. Further experimentation could also explain the effects of the vaccine’s 




Fig. 3 Finalized epitopes for vaccine constructs.16 
 
 
An additional study based at Garden City University focused on a potential multi-epitope 
vaccine candidate targeting the spike glycoprotein due to its role in triggering the stimulation of 
the cytotoxic T lymphocytes (CTL), helper T lymphocytes (HTL) and interferon- γ (IFN- γ). A 
linear vaccine was constructed with 7 CTL, 8 HTL, and 3 IFN- γ epitopes linked by GPGPG 
linkers. GPGPG linkers were chosen due to their ability to enhance solubility and allow the 
adjoining domains to be approachable. Cholera Toxin B (CTB) adjuvant was attached to the N-
terminal by an EAAAK linker to boost a long-lasting immune response. This particular adjuvant 
was chosen due to prior research proving its ability to be a potential viral adjuvant enhancing 
both mucosal and systemic immunity to respiratory syncytial virus by nasal vaccination.21  The 
structural quality of the vaccine construct was tested and validated by Ramachandran plot, Z-
score and ERRAT analysis. The Ramachandran plot indicated that 96.4% of the residues lied in 
the favored region, therefore verifying that the quality of the vaccine construct was reliable. The 
Z-score of -8.1 indicated that the linear vaccine was within range of score of other comparable 
size proteins. The ERRAT analysis scored the vaccine construct as 74.2947, again indicate that 
the modeled structure was valid. All validating methods can be referenced in Figure 4.8  Binding 
affinity was validated via molecular docking to TLR 2, TLR4, MHC I receptor, and MHC II 
receptor. All binding affinities were found to be effective with low HADDOCK scores. The 
vaccine construct was found to be antigenic with a score of 0.5107 via VaxiJen v2.0. The 
proposed vaccine was assessed via an in silico immune stimulation and findings found that the 
vaccine was able to produce specific immune responses necessary to remove the antigen on 
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secondary exposure.  Computational analysis from this study indicated that the vaccine was 
structurally stable, antigenic and immunogenic, making it a possible vaccine candidate against 
SARS-CoV-2.  
 
Fig 4. (A) Linear vaccine construct with CTL, HTL and IFN-γ depicted in sea green, pink and green boxes, 
respectively. EAAAK linker (deep blue) was used for linking the adjuvant and GPGPG linkers (pale green) 
were used for linking the epitopes. (B) 3D model of the final vaccine construct. Red, Limon and Blue represent 
the helical, sheet and loop region, respectively. (C) Validation of the vaccine structure by ERRAT with a score 
of 74.2947. (D) Validation of the structure with a Z-score of − 8.1 using ProSA. (E) Ramachandran plot 
analysing using RAMPAGE 96.4%, 2.9% and 0.7% in the favoured, allowed and outlier region, respectively.8 
 
Lastly, another study collaborating between Guangxi University and Government College 
University Faisalabad (GCUF) focused on the spike glycoprotein of SARS-CoV-2. B-cell and T-
cell epitopes were predicted using ABCpred and IEDB consensus method, respectively. 
Antigenicity and allergenicity of those selected epitopes were then checked by VaxiJen v2.0 and 
Allergen FPv1.0. Further analysis of the epitopes narrowed the vaccine construct to 3 CTL 
epitopes (S1 and M2, 6 HTL epitopes (E3 and M3) and 4 B-cell epitopes (S3 and M1). β-
defensin was again used as an adjuvant and bound to the vaccine construct’s N-terminal by an 
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EAAAK linker. The use of β-defensin was decided due to its relatively small size of 45 amino 
acids as well as its ability to act as an immunomodulator and antimicrobial agent. Subsequently, 
AAY, GPGPG and KK linkers were added to join the CTL, HTL and B cell epitopes, 
respectively. These linkers enhance stability, folding and expression of the vaccine construct. 
The vaccine construct is diagramed in Figure 5 below. Testing of the construct’s structure found 
that it was non-allergenic, highly antigenic (0.6737), and non-toxic. The validity and quality of 
the construct’s structure was validated by a Ramachandran plot indicating 89.4% of the residues 
fell in the favored region, a z-score of -4.8 and an ERRAT score 0f 82.4561. Binding affinity via 
molecular docking was revealed to have stable interactions between the vaccine construct and 
TLR3. All analyses point to a multi-epitopic subunit vaccine structure that is of good quality and 
has the ability to activate an effective immune response.17 Further study through in vitro and in 
vivo experiments could observe the effects of the vaccine construct on SARS-CoV-2. 
 
 
Fig. 5 Schematic diagram of MESV construct.17 
 
Conclusion 
While there is no current vaccine that has been approved by the FDA for COVID-19 infections, 
many vaccine candidates are in clinical trials. There is continued support in exploring multi-
epitope subunit vaccines as these can be capable of producing an immune response. Through 
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immunoinformatics and computational approaches, researchers are able to select antigenic 
epitope targets for vaccine constructs. In addition, outside of being cost-effective, safe, time-
saving, stable, using natural adjuvants and having satisfactory preclinical evaluations, multi-
epitopic vaccine constructs are uncovering various subunit targets of SARS-CoV-2. Analyses of 
these targets have given promising potential as vaccine candidates for SARS-CoV-2. With an 
emerging presence in vaccine candidate studies, multi-epitopic vaccines require additional 
experimentation to develop the rapport of other antiviral agents such as DNA recombinant and 
mRNA vaccines. At this time, studies encourage in vitro and in vivo experimentation for further 
observation of vaccine constructs with hopes of progressing into vaccine development and 
clinical trials. While mRNA vaccines are at the forefront of recent SARS-CoV-2 vaccine 
development, multi-epitopic vaccines still promise potential in future immunization studies. 
Though these vaccines may not be further considered with regards to SARS-CoV-2, studies 
indicate that further experimentation may lead to a legitimate approach in the search for 
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